anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fibrosis is not a disease but rather an outcome of the pathological tissue repair response. Many myofibroblasts are activated which lead to the excessive accumulation of extracellular matrix components such as collagen and fibronectin with fibrosis. A variety of organs, including kidney, liver, lung, heart and skin, can undergo fibrosis under the stimulation of exogenous or endogenous pathogenic factors. The orphan nuclear receptor 4 group A1 (NR4A1) and nuclear receptor 4 group A2(NR4A2)are belong to the nuclear receptor subfamily and inhibit the occurrence and development of fibrosis. NR4A1 is an inhibitory factor of TGF-β signaling transduction. Overexpression of NR4A1 in fibroblasts can reduce TGF-β induced collagen deposition and fibrosis related gene expression. Here, we summarize the current research progress on the NR4A1/2 and fibrosis, providing reference for the treatment of fibrosis.
Greenlight 532nm laser photoselective vaporization of the prostate (PVP) is an appealing treatment modality with hemoglobin as tissue target chromophore and relatively short learning curve. The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser. It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibres required in these situations.
The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercise again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
OBJECTIVE: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health. The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer.
METHODS: Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure.
RESULTS: Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs. radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates.
CONCLUSION: Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01658930.
1,165,144. Optically active compounds. SCHERING A.G. 2 Sept., 1966 [14 Sept., 1965], No. 24031/69. Divided out of 1,165,143. Headings C2C and C2U. Novel 8(14)-seco-steroid of the general formula in which Ca represents an asymmetric carbon atom in the 13-position of the seco-steroid, X represents a hydrogen atom, a free, esterified or etherified hydroxyl group, a free or esterified carboxyl group or a saturated or unsatured aliphatic hydrocarbon group containing 1 to 4 carbon atoms which may be substituted by a halogen atom or by a free or functionally converted hydroxyl, amino or carboxyl group, Y represents a steroid residue attached to the B-carbon atom and Z and Z<SP>1</SP> together with the Ca carbon atom represent a D- or D-homo ring comprising a first group and a second group which groups are present in positions that are symmetrical with respect to the Ca carbon atom, the first group being selected from the list consisting of the following groups: in which R 1  represents a hydrogen atom or an acyl, aryl or alkyl group, in which R 2  represents an H atom, or an OH, O-alkyl, O-aryl or NH 2  group, in which R 3  represents a hydrogen atom or an alkyl, aryl or acyl group, in which Hal represents a halogen atom, and the second group being a group that is obtainable in an organic compound from the first group by treatment (under conditions suitable for fermentation) with a micro-organism or with an enzyme of such a micro-organism, the remainder of the D- or D-homo-ring being symmetrical with respect to the Ca carbon atom, are obtained in a process wherein a compound of the formula wherein X, Y and Z have the above defined meanings and Ci represents an optically inactive carbon atom, is treated under conditions suitable for fermentation with a micro-organism or with an enzyme of such a micro-organism. Suitable micro-organisms are fungi, yeasts or bacteria. The 8(14)-seco steroids, may be cyclized to form steroids containing a closed C-ring, if desired after protecting any sensitive groups not taking part in the cyclization. The products of the ring closure reaction may be reduced to saturate double bonds therein, oxidized to convert 17-OH to 17-keto and a group in 3- position may be functionally converted, e.g. by saponification, etherification or esterification.
PURPOSE: To obtain the subject skin preparation for external use by reaction of an amino sugar as a stable natural emulsifier excellent in emulsification characteristics with an alkenyl succinic anhydride as hydrophobic group and an organic acid anhydride as hydrophilic group. CONSTITUTION: This skin preparation for external use contains an amino sugar derivative as emulsifier which is obtained by reaction of amino sugar (esp. pref. chitosan) with an alkenyl succinic anhydride as hydrophobic group (esp. pref. octenyl succinic anhydride) and an organic acid anhydride as hydrophilic group (esp. pref. succinic anhydride). Specifically, the amino sugar is obtained by adding the alkenyl succinic anhydride and organic acid anhydride to the amino sugar followed by carrying out reaction under agitation at both specified pH level and temperature. The amino sugar, a natural emulsifier, can be used in combination with other natural-based and/or synthetic emulsifier(s). In particular, combination of the amino sugar with a synthetic emulsifier reduces its use, leading to improving the safety of this cosmetic, and resulting in great advantages.  This skin preparation can be used as cream, lotion, milky lotion or shampoo.
PURPOSE:To prepare an ibuprofen formulation which is excellent in effectiveness and safety because it has a much more improved antipyretic action and also gastrointestial troubles as its adverse effect is reduced. CONSTITUTION:Ibuprofen is combined with aminoacetic acid in such an amount that the antipyretic action of ibuprofen is increased to give this ibuprofen formulation. The amount of aminoacetic acid is preferably 1-100 pts.wt. particularly 1-20 pts.wt. per 10 pts.wt. of ibuprofen. The daily dose of ibuprofen in this formulatiom is 100-1,000mg, preferably 200-600mg/adult and it is given one or several portions a day.
The invention finds application in biotechnology. It relates to polypeptides interacting with caspase-8, in particular to a polypeptide and its variants, the polypeptide possessing an isolated amino acid sequence of clone p74 and being capable of interacting with subunit 1 and/or subunit 2 of caspase-8. A DNA sequence is disclosed as well coding the polypeptide according to the invention. A vector is described comprising said DNA, as well as a host cell capable of reproducing said polypeptide. A ribozyme specific for said DNA, as well as an antisense oligonucleotide and an antibody against the polypeptide applied for. The polypeptide, the ribozyme and the antibody are used to modulate caspase-8 activity, apoptosis and respectively as a medicament in the treatment of a number of capsase-8 related diseases. The antibody against the polypeptide applied for may be used for immunoanalysis, and the polypeptide itself may be used for identification and separation of proteins with similar activity.
PURPOSE:A cosmetic, containing an extract component obtained by extracting a component from the root of Astragalus hoantchy Franch. as a natural product active constituent and further a water-soluble high polymer, and having improved skin beautifying, whitening and beautifying an humectant effect. CONSTITUTION:A cosmetic obtained by incorporating an extract prepared by extraction from mainly the dried root of Astragalus hoantchy Franch., e.g. Astragalus membranaceus Bunge, Atragalus mongholicus Bunge or Hedysarum polybotrys, known as a crude drug, e.g. tonic, diuretic, antinephritis, hypotensive, vasodilator or cardiotonic action, with an organic solvent and/or water in an amount of 0.01-10wt%, preferably 0.1-5wt% based on the total weight of the cosmetic, and further a water-soluble high polymer, e.g. polypeptide, water- soluble collagen or gelatin, in an amount of 0.001-1wt% based on the total weight with other components. EFFECT:Favorable effect, e.g. tension, gloss, smoothness of freshness, is produced.
The invention relates to genetic engineering, in particular to a binding protein (LvFABP) of pathogenic vibrio PirB protein and application thereof in preventing and treating acute hepatopancreatic necrosis (AHPND) of prawns. The base sequence of the binding protein of the pathogenic vibrio PirB protein is shown as SEQ ID NO. 1. Use of double-stranded RNA (dsLvFABP) of a partial gene sequence of a binding protein of a PirB protein of pathogenic vibrio shown in SEQ ID No. 1 for inhibiting pathogenic vibrio infection. The base sequence of double-stranded RNA (dsLvFABP) of part of the gene sequence of the binding protein of the pathogenic vibrio PirB protein is shown as SEQ ID NO. 2. The double-stranded RNA injection can effectively reduce the death rate of the prawns after pathogenic vibrio infection, and has remarkable protection effect on prawn culture. The LvFABP gene and the coded protein thereof can be used for molecular markers for breeding prawn varieties, and double-stranded RNA or protein antibodies can be used for disease control, thereby having good application prospects in the control of prawn AHPND.
60 Chinese men aged between 21 and 60 years old with overweight/obesity (25 kg/m2 \<BMI \< 32.5 kg/m2) and prediabetes will be recruited.The participants will be divided into three age-matched groups (n=20 in each group),including high intensity exercise, moderate intensity exercise, and non-exercise groups. The suitability of each participant for physical exercise will be assessed by an in-house exercise specialist, based on parameters of blood pressure, strength, cardiovascular fitness, balance, flexibility. The exercise program will consist of three sessions per week over the course of 12 weeks, under the supervision of our in-house exercise specialists and physiologists. Each session will comprise of warm-up, resistance and aerobic training components and a cool-down. The high intensity training (aerobic combined with strength training) will consist of six exercises of three sets each, with each exercise set at an intensity of 6 to 10 repetition maximum. Intensity, volume and exercise selection will be varied both within the week and over the 12 week program in a periodised system designed to maximize muscle hypertrophy and strength gain. Exercise intensity will be at 60 to 80% of estimated heart rate maximum. Moderate intensity training (Aerobic training) will be conducted on a variety of ergometers including treadmill, cycle, rowing and cross training machines. The non-exercise group (delayed group) will be used as placebo control, and will participate in the training group at the later stage.
Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect. The second dose can be administered within 24 hours after the first dose.
The invention relates to a preparation method and application of a metal oxide nano drug delivery system based on a gold nanorod loaded with a chemotherapeutic drug. The system uses gold nanorods as a carrier, and loads metal oxides and chemotherapeutics on the gold nanorods to form the yolk shell nano diagnosis and treatment reagent for three-mode integrated treatment with photodynamic-photothermal-chemical action. In short, gold nanorods play a key role in photothermal action as good photothermal materials and carriers. The metal oxide layer not only can load chemotherapeutic drugs, but also can relieve the hypoxia state in the tumor environment and effectively inhibit the growth of tumors. Meanwhile, the chemotherapeutic drug doxorubicin plays a role in chemotherapy, and the photosensitizer indocyanine green plays a role in photodynamic therapy, so that triple combination therapy of photothermal, chemotherapy and photodynamic therapy of liver cancer is realized. The invention provides a novel nano-drug delivery system, which can realize photothermal treatment, chemotherapy and photodynamic treatment of liver cancer and can realize more efficient treatment effect.
Pain after cesarean section (CS), usually described as strong, is an obstacle to good mother-child interaction and post-operative rehabilitation. Its management is important for a quick recovery and allow the mother to take care and link with her newborn. Currently, intrathecal opioids are the most commonly used technique and provide the foundation for post-cesarean analgesia. This technique combined with multimodal analgesia reduces the doses of morphine consumed, including these side effects. Spinal anesthesia is the standard anesthetic technique for caesarean section; it offers several advantages including the possibility of prescribing oral analgesics. An ideal analgesic protocol is one that is simple to implement, cost-effective, and has minimal impact on the work staff. It would have a good safety profile, a low incidence of side effects and complications, and respond to wide inter-patient variability. It relieves the mother of high quality pain while having minimal interference with her, newborn care and anesthesia while allowing safe breastfeeding.

The aim of this work is to compare the quality of an multimodal oral analgesia with intravenous analgesia and to demonstrate non-inferiority of the oral route pain relieve in postoperative caesarean section period. The secondary objectives was to evaluate the maternal tolerance of the drugs (piroxicam, nefopam, paracetamol) used postoperatively of a caesarean section.
This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
Tibial shaft fracture is a common injury worldwide. Their treatment, prognosis, and outcome are determined by the mechanism of injury, presence of communition, soft tissue injury and displacement. In developing countries, lack of education,socioeconomic backgrounds, delay in presentation and appropriate planning for surgery add further to complicate the situation and may end in delayed union, non-union, multiple surgeries and ultimate results in increased morbidity. This study was conducted to determine the outcome of open tibia shaft fracture treated with Ilizarov or AO External Fixator. It was retrospective Cohort study. Two groups were compared in terms of fracture healing, mechanism of injury, fracture classification, Participant's ambulation at discharge, New Injury Severity Score (NISS), duration of hospital stay, duration of fracture union, need for secondary procedures and complications. Investigators concluded that circular fixator application has favorable outcomes for Gustilo grade III open tibial shaft fractures as compared to uniplanar external fixator.
A novel strain of lactic acid bacteria was found to be heat resistant and able to grow in a sulfur-limiting medium (SLM) containing a high concentration of sodium selenite. The microorganism is a non-spore forming and Gram-positive coccus, which is identified with >90% confidence using the API biochemical and sugar fermentation tests, ribotyoing and 16S rRNA sequencing as  Pediococcus pentosaceus  SP80. In the current study,  P. pentosaceus  SP80 grown on SLM containing 250 ppm sodium selenite produced both organic and inorganic forms of selenium. These selenium compounds can be separated using an anion exchange chromatography technique. The concentrations of selenium detected in the organic and inorganic fractions were 4.34 and 21.7 ppm, respectively. Selenium-enriched bacteria are useful as a source of selenium for supplementing the diets of animals and humans. Animals fed efficacious amounts of the selenium-enriched bacteria show improved feed conversion rates and higher levels of glutathione peroxidase (GPx) activity in heart, kidney and liver tissues indicating an increased absorption and retention of selenium over control diets.
The invention relates to a biological system for diminishing cell growth or inducing selective killing of target cells, in particular pathogenic bacterial or fungal cells, or cancer cells. The biological system according to the invention is based on toxin-antitoxin systems, as found in prokaryotic plasmids and their host chromosomes. The biological system comprises a vehicle with a first nucleic acid sequence or amino acid sequence encoding for a prokaryotic toxin of a prokaryotic toxin-antitoxin pair, and a second nucleic acid sequence or amino acid sequence encoding for the corresponding prokaryotic antitoxin of the prokaryotic toxin-antitoxin pair. The system is characterized in that the toxin and/or the antitoxin is operably linked to a protein output modifier (POM) that comprises a nucleic acid sequence or amino acid sequence that modifies the relative rate of transcription, mRNA stability, mRNA translatability or protein stability of the toxin and/or antitoxin thereby changing the relative ratio in the concentration of the toxin and/or the antitoxin within the target cells and/or, where applicable, within non-target cells by either decreasing the antitoxin outputs in the target cells (killing) and/or increasing the antitoxin outputs in the non-target cells (protection) relative to the toxin outputs, and/or by increasing the toxin outputs in the target cells (killing) and/or decreasing the toxin outputs in the non-target cells (protection) relative to the antitoxin outputs. The invention also relates to a pharmacological composition to be used in the treatment of pathogenic diseases. The invention further relates to the use of the biological system for therapy of a pathological condition, diagnostics, theranosis, drug discovery, Screening, creating animal models, target molecule identification and validation. In a further aspect, the invention also relates to a drug delivery system for delivering a vehicle to target cells by means of biologically-derived nanocells (minicells). The invention also relates to a method for delivery of a substance to target cells.
Online training for healthcare professionals which will follow a protocol made especially for this research. The online training is composed by 4 modules and each module has 3 meetings. Each meeting has 35 minutes long.
An acetylenic alcohol compound or extract of Reniochalina sp. is provided to exhibit growth control activity effects on various cancer cell lines, and to be used as pharmaceutical compositions for prevention and treatment of cancer. An acetylenic alcohol compound or pharmaceutically acceptable salts thereof has a structure represented by chemical formula 1 or 2. In chemical formula 1, n is an integer of 20-30. In chemical formula 2, m is an integer of 0-3 and n is an integer of 0-3. The acetylenic alcohol compound is a (3R)-hydroxyoctatriacont-(4E)-en-1-yne compound or pharmaceutically acceptable salts thereof; or a (3R)-hydroxy-35-methylheptatriacont-(4E)-en-1-yne compound or pharmaceutically acceptable salts thereof.
PURPOSE: A pharmaceutical composition containing, as an active ingredient, magnolol or a pharmaceutically acceptable salt derived from the extract of Magnolia Bark(Cortex Magnoliae Offcinalis) or processed Magnolia Bark is provided. The composition is effective for prevention and treatment of diabetic complications such as retinopathy, cataract, nephropathy, neuropathy or the like. CONSTITUTION: The pharmaceutical composition for prevention and treatment of diabetic complications contains magnolol or a pharmaceutically acceptable salt as an effective ingredient. The magnolol is derived from the extract of Magnolia Bark obtained by grinding Magnolia Bark and extracting it in alcohol or an aqueous alcohol solution. The Magnolia Bark extract is also obtained by grinding a processed Magnolia Bark and then extracting it in alcohol or an aqueous solution. The processed Magnolia Bark is prepared by heating Magnolia Bark, Zingiberis Rhizoma and water at 70 to 100deg.C, drying and then grinding it.
Intravenous ketamine will be initiated following aneurysm securement at 0.5mg/kg/h and will be titratable by 0.2mg/kg/h every 20min to a Richmond Agitation Sedation Scale (RASS) goal of 0 to -1 (or as otherwise clinically indicated). Ketamine boluses will be available at 0.5mg/kg every 1hr as needed for inadequate sedation or breakthrough agitation. An additional 0.5mg/kg bolus may be utilized prior to initiating the ketamine infusion, or as needed at the discretion of the clinician. The maximum ketamine infusion dose will be limited to 4mg/kg/h. A fixed-dose propofol infusion at 10mcg/kg/min will simultaneously be administered to minimize the potential psychomimetic side effects of ketamine. This sedation paradigm will continue for up to 10 days post-bleed or until the study participant no longer requires sedation, whichever occurs earlier. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.